- Home
- GROY vs AQST Comparison
GROY vs AQST Comparison
Compare GROY & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROY
- AQST
- Stock Information
- Founded
- GROY 2020
- AQST 2004
- Country
- GROY Canada
- AQST United States
- Employees
- GROY N/A
- AQST N/A
- Industry
- GROY
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- GROY
- AQST Health Care
- Exchange
- GROY Nasdaq
- AQST Nasdaq
- Market Cap
- GROY 322.2M
- AQST 272.9M
- IPO Year
- GROY 2021
- AQST 2018
- Fundamental
- Price
- GROY $2.26
- AQST $3.26
- Analyst Decision
- GROY Strong Buy
- AQST Strong Buy
- Analyst Count
- GROY 3
- AQST 6
- Target Price
- GROY $3.67
- AQST $10.67
- AVG Volume (30 Days)
- GROY 2.5M
- AQST 1.6M
- Earning Date
- GROY 08-12-2025
- AQST 08-05-2025
- Dividend Yield
- GROY N/A
- AQST N/A
- EPS Growth
- GROY N/A
- AQST N/A
- EPS
- GROY N/A
- AQST N/A
- Revenue
- GROY $10,347,000.00
- AQST $54,228,000.00
- Revenue This Year
- GROY $88.55
- AQST N/A
- Revenue Next Year
- GROY $52.87
- AQST $45.71
- P/E Ratio
- GROY N/A
- AQST N/A
- Revenue Growth
- GROY 99.94
- AQST 5.29
- 52 Week Low
- GROY $1.16
- AQST $2.12
- 52 Week High
- GROY $2.49
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- GROY 66.38
- AQST 56.20
- Support Level
- GROY $2.16
- AQST $3.20
- Resistance Level
- GROY $2.49
- AQST $3.46
- Average True Range (ATR)
- GROY 0.12
- AQST 0.25
- MACD
- GROY 0.01
- AQST -0.02
- Stochastic Oscillator
- GROY 63.28
- AQST 25.33
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.